Movano up on positive preliminary trial data for women health wearable

Corvex

14/12/2022 18:04

** Healthcare solutions developer Movano Inc's shares
 MOVE.O  up 2.4% at $1.7
    ** Co says preliminary results from trial testing its
wearable product, smart ring, shows high accuracy in measuring
blood oxygen saturation (SpO2) and generating heart rate data 
    ** Smart ring is a women-centric health wearable that
provides personalized intelligent feedback to help mitigate the
risks associated with chronic disease - MOVE
    ** The product resulted in an approximate 2% margin of
error, well below the FDA consensus standard of 4% for measuring
SpO2 - Co 
    ** MOVE expects to file for U.S. FDA clearance of the health
ring's metrics in 2023  
    ** Including session moves, stock down ~56% YTD 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))